SynthesisSchmerz (Berlin, Germany)2017
[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].
Synthesis in Schmerz (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Recommendations of the second update of the LONTS guidelines : Long-term opioid therapy for chronic noncancer pain].Schmerz (Berlin, Germany) · 2020Pooled it
- Cannabinoids in Pain Management and Palliative Medicine.Deutsches Arzteblatt international · 2017Pooled it
- [General treatment principles, coordination of care and patient education in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].Schmerz (Berlin, Germany) · 2017Pooled it
- Cost-Effectiveness of Pregabalin, Duloxetine, and Milnacipran vs Amitriptyline for Moderate to Severe Fibromyalgia.JAMA network open · 2026Article
- Patient Version of Guideline for Fibromyalgia (2025 Edition).Journal of evidence-based medicine · 2025Article
- [Effects of a multimodal inpatient treatment for patients with fibromyalgia syndrome at the Rhineland-Palatinate Acute Rheumatology Center].Zeitschrift fur Rheumatologie · 2025Article
- The impact of a heat therapy intervention on pain and fibromyalgia symptoms in patients with fibromyalgia: a pilot study.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- [Procedures of complementary medicine in rheumatology].Zeitschrift fur Rheumatologie · 2024Review
- [Tetrahydrocannabinol (THC) in patients with fibromyalgia syndrome (FMS) : A retrospective study of changes in pain, psychometric variables, and analgesic consumption during inpatient interdisciplinary multimodal pain therapy (IMPT)].Schmerz (Berlin, Germany) · 2024Article
- Distinguishing fibromyalgia syndrome from small fiber neuropathy: a clinical guide.Pain reports · 2024Article
- Article
- Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review.Arthritis care & research · 2023Review
- Mild Water-Filtered Infrared-A Whole-Body Hyperthermia Reduces Pain in Patients with Fibromyalgia Syndrome-A Randomized Sham-Controlled Trial.Journal of clinical medicine · 2023Article
- Adherence to Clinical Guidelines for Fibromyalgia: Help or Hindrance?Canadian journal of pain = Revue canadienne de la douleur · 2023Article
- Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis.Clinical rheumatology · 2022Review
- Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study.Pain research & management · 2022Article
- Disentangling Diagnosis and Management of Fibromyalgia.Journal of rheumatic diseases · 2022Review
- The Importance of Daily Activity for Reducing Fibromyalgia Symptoms: A Retrospective "Real World" Data Comparison of two Multimodal Treatment Programs.Archives of rheumatology · 2020Article
- [Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].Schmerz (Berlin, Germany) · 2019Review
- Rethinking the criteria for fibromyalgia in 2019: the ABC indicators.Journal of pain research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017.
methodsThe guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n =8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A literature search for systematic reviews of randomized controlled drug trials from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND
conclusionAmitriptyline and duloxetine are recommended in the case of comorbid depressive disorders or generalized anxiety disorder and pregabalin in the case of generalized anxiety disorder. Off-label use of duloxetine and pregabalin can be considered if there are no comorbid mental disorders or no generalized anxiety disorder. Strong opioids are not recommended.
Indexed as
Identifiers
28493231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.